Five-year agreement will pay for equipment to develop, produce and certify active pharmaceutical ingredients
South Africa will receive €20 million (US$21m) from Germany to boost vaccine production under a financing deal finalised this month.
The five-year deal will pay for equipment for the development, production and certification of active pharmaceutical ingredients for vaccines in South Africa.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.